TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01443169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 - Treatment C: Controlled Release Pregabalin
Description: 330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2 - Treatment E: Immediate Release Pregabalin
Description: 300 mg IR capsule administered in the evening in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 - Treatment C: Controlled Release Pregabalin
Description: 330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 - Treatment A: Controlled Release Pregabalin
Description: 330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 - Treatment D: Controlled Release Pregabalin
Description: 330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 - Treatment B: Controlled Release Pregabalin
Description: 330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3 - Treatment E: Immediate Release Pregabalin
Description: 300 mg IR capsule administered in the evening in the fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 - Treatment D: Controlled Release Pregabalin
Description: 330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 - Treatment C: Controlled Release Pregabalin
Description: 330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 - Treatment B: Controlled Release Pregabalin
Description: 330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 - Treatment A: Controlled Release Pregabalin
Description: 330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4 - Treatment E: Immediate Release Pregabalin
Description: 300 mg IR capsule administered in the evening in the fasted state.
Study: NCT03620799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: A manual intervention technique is employed to the intervention group based on a roller treatment.
Study: NCT04062695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 MG Oral Tablet [Xeljanz]
Description: verum tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: tablets containing placebo
Study: NCT02970383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial prescription for 10 narcotic tabs
Description: Reduced number of pills in initial prescription post-operatively

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inital prescription for 30 narcotic tabs
Study: NCT02801331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Vibrotactile Stimulation (SVS)
Description: Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle, stochastic vibration during mattress stimulations.
Study: NCT03837717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holding
Description: Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holding
Description: Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Holding
Description: Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Holding
Description: Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
Study: NCT01368419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 6～15MV X-ray, 2Gy/time，5times/week，6 weeks
Study: NCT01257347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure of adherence report to clinician
Description: During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (\<10 minutes) in the interpretation and use of the report at the time of enrollment.

Intervention type: DEVICE
Group type: OTHER
Intervention: MedSignals pillbox
Description: (Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedSignals pillbox
Description: (Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
Study: NCT02642705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training N
Description: Exercise training and ambient air breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training H
Description: Exercise training and hypoxic breathing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant load exercise training N
Description: Exercise training and ambient air breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant load exercise training H
Description: Exercise training and hypoxic breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic conditioning at rest
Description: Hypoxic breathing at rest

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxic conditioning at rest
Description: Normoxic breathing at rest (placebo)
Study: NCT04108078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Policy Plus (HP+)
Description: HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Many Men Many Voices (3MV)
Description: 3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Education, Empathy and Empowerment (HIVE3)
Description: The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
Study: NCT03122171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Treatment
Description: Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
Study: NCT04381065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal KinetiGraph® (PKG®) System
Description: The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch~* Data-driven report known as the PKG®~The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® also provides an assessment of daytime somnolence and an indication of propensity for impulsive behaviors.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Personal KinetiGraph® (PKG®) Watch
Description: The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch
Study: NCT00053625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
Study: NCT02102555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: Single dose of one gram of IV acetaminophen given in pre-operative area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (IV normal saline)
Study: NCT01232283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical or Phototherapy Therapy
Description: Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical or Phototherapy Therapy
Description: Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
Study: NCT02986464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Prototype
Description: VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pharmacological Treatment
Description: According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
Study: NCT00671788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02668640

Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: Pre-filled syringe, administered by subcutaneous injection
Study: NCT03912389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or carboplatin)
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin (or carboplatin)
Description: IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT01811238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone
Description: Targin 5mg, 10mg, 20mg up to 40mg b.i.d
Study: NCT04411615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: rTG form Omega-3
Study: NCT00828711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 100
Description: Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 150
Description: Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 200
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study: NCT03035448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Presentation
Description: Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Presentation
Description: Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
Study: NCT06405919

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology
Description: Thyroidectomy for patients and histological examination of specimen to determine incidence of malignancy.
Study: NCT01033838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectosigmoid resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rectosigmoid resection
Study: NCT01164761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace
Description: Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
Study: NCT02757157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based walking
Description: Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based walking
Description: Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Land-based walking
Description: Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Land-based walking
Description: Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.
Study: NCT03710512

Intervention type: PROCEDURE
Intervention: Bilateral sagittal split osteotomy
Description: Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies

Intervention type: PROCEDURE
Intervention: Bilateral sagittal split osteotomy
Description: Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies
Study: NCT01198912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: during 56 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline 100 mg
Description: during 56 days